NYSEHealth CareMedical - DevicesSnapshot 2026-10-15
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
Living Fair Value by QuarterlyIQ
A valuation that evolves as the business changes.
A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.
View Living FV report and workflow4 key conditions need to be met for the investment thesis to play out.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Dividend increases annually, continuing 49 years of growth | The company raised its dividend for 49 years in a row. | Intact | Dividend per share does not increase in FY26 | Dividend per share: $0.72 per share FY2027-Q1; GAAP. Published target: Dividend per share increases to $0.72 in Q4 FY26. Target period is not explicitly aligned with this observation. Source published Sep 3, 20260.72 USD/share · source valueSource reportLast status assessment Oct 15, 2026Measurement sourceconsolidated · GAAP FY2027-Q1 · Period ending Jul 31, 2026 Source: company_financial_results. Reference: ba052f00-742d-46ce-afde-5c0256244f91. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 4 of last 4 quarters. Medtronic increased its quarterly dividend to $0.72 in Q1 FY27, marking the 49th consecutive year of dividend increases. This consistent dividend growth reflects management's ongoing commitment to shareholder returns and is delivering as stated. Delivery assessment Oct 15, 2026 |
Strong growth in key franchises like Cardiac Ablation and Diabetes | Key franchises like Cardiac Ablation grew 78% last quarter. | Under Pressure | Cardiac Ablation growth falls below 6% in Q4 FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 6 of last 8 quarters. Key franchises like Cardiac Ablation Solutions grew by 78% in 2026-Q4 and Diabetes revenue increased 15%. New product launches such as Hugo robotic surgery and MiniMed 780G contributed to growth. The trajectory shows delivering strong growth in targeted franchises. Delivery assessment Oct 15, 2026 |
Non-GAAP EPS grows to about $6.00 in FY27 | Medtronic grows sales about 7% a year. | Intact | EPS falls below $5.60 in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 8 of last 8 quarters. Medtronic's FY26 non-GAAP diluted EPS grew modestly to $5.53 from $5.49 in FY25. The company guides FY27 EPS to $5.90-$6.00, implying continued earnings leverage. The trajectory matches management's commitment to maintain and raise EPS guidance. Delivery assessment Oct 15, 2026 |
Organic revenue growth accelerates to about 7% in FY27 | A primary condition in Medtronic's published investment case. The stated target is 6.75%-7.25% YoY growth. | Intact | organic revenue growth falls below 5% in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 8 of last 8 quarters. Medtronic reported FY26 organic revenue growth of 5.8%, improving from 4.9% in FY25, and guides FY27 organic growth to 6.75%-7.25%. The trajectory shows delivering sustained acceleration in organic revenue growth consistent with management's stated priority. Delivery assessment Oct 15, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsLatest: 19 Buy / Strong Buy · 10 Hold · 0 Sell / Strong Sell
Recent actions · Sep 16–Oct 15 · 2 recorded
0 raises · 1 cuts · 0 unchanged · 1 without a comparable prior
Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 17, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a durable compounder with a focus on organic revenue growth and earnings leverage. The current thesis state is intact, reflecting recent earnings beats and a strong trajectory in key franchises.
The market appears to have priced in a neutral valuation, with MDT being seen as cheap compared to its peers. There is a slight expectations gap, indicating that some positive performance may not be fully reflected in the stock's current valuation.
Fundamentals are likely to continue showing strength, as management is on track to achieve its growth targets. However, there is a moderate risk due to potential economic headwinds and historical performance issues.
The thesis hinges on maintaining guidance in upcoming calls and the overall health of the healthcare sector. Key earnings from sector leaders could also influence MDT's performance positively.
Overall, MDT's trajectory looks stable for the next 1 to 3 years, but it faces risks that could impact its performance. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.